Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
about
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Bedaquiline: a review of human pharmacokinetics and drug-drug interactionsRising to the challenge: new therapies for tuberculosisCurrent strategies to treat tuberculosisBedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.Insights into the pharmacokinetic properties of antitubercular drugs.Recent advances in tuberculosis: New drugs and treatment regimens.Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery.A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisRifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.New drugs to treat tuberculosis.TB and HIV Therapeutics: Pharmacology Research Priorities.Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.TMC207 becomes bedaquiline, a new anti-TB drug.Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.Bedaquiline for the treatment of drug-resistant tuberculosis.Management of drug resistantTB in patients with HIV co-infection.After 40 years, new medicine for combating TB.Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".A Bayesian response-adaptive trial in tuberculosis: The endTB trial.Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
P2860
Q26771997-F28CB4EF-396F-4DA8-BE68-532BD8C0FB4AQ26824413-95823CEB-7D28-4FE6-8DEE-8926A16FE8ECQ26864991-68B54DB8-612D-4CB4-A0C5-84F77512916BQ27011672-C72534E5-FF61-45B1-99A6-3CE9D05E539FQ28075252-F5CFE3F7-DC3D-4DA8-A365-9BB14A262049Q30249515-1C8A78AE-7B88-4977-A1C6-257E572572ACQ30251497-EFB91DEA-ADBA-4806-AE78-78A8AEDA4765Q30360811-129AE37B-8B2B-497E-B291-C3D5A65DF10AQ33901126-1E080FF4-AF44-49A8-995C-EABC402BE50BQ33939074-A12C0BCF-6724-4355-9C97-CEE81BF25561Q35167188-B3EADDFB-3E5F-4E50-B6CD-20F6773ADF0AQ36018409-B7756FBB-3031-43DA-A782-F409C53F25CFQ36099838-290AD9E0-D882-47DB-A418-BD2FA6D9DD17Q36445099-775512A3-8D9B-4C98-A2E9-B407B4A6D55AQ37026667-1E949444-9B2E-41C3-8576-D382B2CA5DADQ38135901-11CEF0FF-73EA-4618-BD85-031FCCB11510Q38164652-BD7A06DD-15AB-45EF-8B24-52BB767D6A87Q38190535-4F024197-39B7-4304-A259-AD3F030EBC4CQ38247442-77195D55-ADA6-4029-8610-35A70BBDA8C5Q38386950-D05C53F5-A4BF-4243-B539-6B2D203BBDD3Q38610637-AD00F3BF-CCB8-4429-9E2B-94F5AD692191Q42119482-1AC4AAF0-7D13-4822-9407-EE9F7A7F41C7Q50072871-68D4BF22-9CFD-4533-B188-E47A3D562E50Q50097194-87336CF1-F415-4455-B701-EC145DAFBCA9Q50170378-EE9C6E9A-D3A4-473A-A59F-A05714540FD0Q58788916-CA9D84E8-E163-4808-A73C-A89B1131757A
P2860
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@ast
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@en
type
label
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@ast
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@en
prefLabel
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@ast
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@en
P2093
P2860
P1476
Safety, tolerability, and phar ...... ical Trials Group Study A5267.
@en
P2093
ACTG 5267 Study Team
Amita Gupta
Charles Flexner
David W Haas
Francesca Aweeka
Ilene Wiggins
Jeong-Gun Park
Kelly E Dooley
Patricia Lizak
Reena Allen
P2860
P304
P356
10.1097/QAI.0B013E3182410503
P407
P577
2012-04-01T00:00:00Z